

Milbeguard Duo 12.5 mg / 125 mg chewable tablets for dogs

Authorised

- Milbemyacin oxime
- Praziquantel

Product identification

Medicine name:

Milbeguard Duo 12.5 mg / 125 mg chewable tablets for dogs

Active substance:

Milbemyacin oxime

Praziquantel

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Milbemyacin oxime

12.50 milligram(s) / 1.00 Tablet

Praziquantel

125.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP54AB51

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Poland

Package description:

Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 1 blister of 2 tablets (2 tablets).

Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 2 blisters of 2 tablets (4 tablets).

Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 5 blisters of 2 tablets (10 tablets).

Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 12 blisters of 2 tablets (24 tablets).

Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 24 blisters of 2 tablets (48 tablets).

Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 50 blisters of 2 tablets (100 tablets).

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 18 of Regulation (EU) 2019/6)

Marketing authorisation holder:

Ceva Animal Health Polska Sp. z o.o.

Marketing authorisation date:

8/11/2023

Manufacturing sites for batch release:

Ceva Sante Animale

Responsible authority:

Office For Registration Of Medicinal Products Medical Devices And Biocidal Products

Authorisation number:

3283

Date of authorisation status change:

8/11/2023

Reference member state:

Ireland

Procedure number:

IE/V/0780/002

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland
France Germany Greece Hungary Italy Latvia Lithuania Luxembourg
Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain
Sweden United Kingdom (Northern Ireland)

Generic of:

600000042342

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)

Published on: 3/05/2024

Updated on: 13/03/2026

[Download](#)

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

English (PDF)

Published on: 5/04/2026

[Download](#)